Ardelyx, Inc. (NASDAQ:ARDX) Stock Has Average Target Price of $13.60

Shares of Ardelyx, Inc. (NASDAQ:ARDX) have been assigned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $13.60.

A number of research firms recently issued reports on ARDX. TD Cowen started coverage on shares of Ardelyx in a research report on Wednesday, November 4th. They set a “strong-buy” rating on the stock. Citigroup cut their price target on shares of Ardelyx from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, August 10th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Ardelyx in a research report on Friday, August 7th. BTIG Research dropped their target price on shares of Ardelyx from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, November 9th. Finally, Zacks Research raised shares of Ardelyx from a “strong sell” rating to a “hold” rating in a research report on Friday, October 16th.

Ardelyx News Summary

These are some of the ARDX news items that stood out recently:

• Positive Sentiment: A separate report cites an average analyst price target of $13.60, which may offer a more optimistic counterpoint to the legal headlines. Ardelyx, Inc. Stock Has Average Price Target of $13.60
• Neutral Sentiment: Several firms reiterated that investors who bought ARDX shares during January 13, 2025–August 6, 2026 may seek lead-plaintiff status by November 16, 2026. These notices repeat the same deadline and do not report a new court ruling or resolution. Faruqi & Faruqi deadline reminder
• Negative Sentiment: BTIG Research trimmed its price target for ARDX, a potentially negative analyst signal. The supplied headline does not specify the revised target. BTIG Research trims Ardelyx price target

Insiders Place Their Bets

In other Ardelyx news, insider Laura A. Williams sold 10,739 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $41,452.54. Following the completion of the sale, the insider directly owned 367,456 shares of the company’s stock, valued at $1,418,380.16. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Michael Raab sold 58,574 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $3.86, for a total value of $226,095.64. Following the completion of the sale, the chief executive officer owned 1,619,792 shares in the company, valued at approximately $6,252,397.12. The trade was a 3.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 126,059 shares of company stock valued at $486,588 in the last quarter. 5.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ardelyx

Large investors have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. bought a new position in Ardelyx in the 2nd quarter worth about $35,000. Sterling Capital Management LLC grew its holdings in Ardelyx by 842.7% during the 3rd quarter. Sterling Capital Management LLC now owns 8,088 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 7,230 shares in the last quarter. SCS Capital Management LLC bought a new stake in shares of Ardelyx during the second quarter valued at about $52,000. ADAR1 Capital Management LLC bought a new stake in shares of Ardelyx during the second quarter valued at about $56,000. Finally, PVG Asset Management Corp purchased a new stake in shares of Ardelyx in the first quarter worth about $65,000. 58.92% of the stock is owned by institutional investors.

Ardelyx Stock Performance

Shares of NASDAQ ARDX traded down $0.03 during midday trading on Thursday, hitting $3.09. 2,380,473 shares of the company’s stock were exchanged, compared to its average volume of 4,883,672. Ardelyx has a 12 month low of $2.80 and a 12 month high of $8.40. The firm has a market capitalization of $776.74 million, a PE ratio of -14.05 and a beta of 0.79. The company’s 50 day moving average price is $3.28 and its 200 day moving average price is $5.11. The company has a quick ratio of 3.26, a current ratio of 3.45 and a debt-to-equity ratio of 1.54.

Ardelyx Company Profile

Ardelyx, Inc. is a biopharmaceutical company that develops and commercializes medicines for kidney and gastrointestinal diseases. Founded in 2007, the company has focused on treatments that work in the gastrointestinal tract, including therapies based on tenapanor. Ardelyx markets IBSRELA (tenapanor) in the United States for adults with irritable bowel syndrome with constipation. It also markets XPHOZAH (tenapanor) to help control serum phosphorus in adults with chronic kidney disease who are on dialysis.